ABERRANT JAK-STAT SIGNALING DUE TO LNK MUTATIONS IN MYELOPROLIFERATIVE NEOPLASMS
骨髓增生性肿瘤中 LNK 突变导致 JAK-STAT 信号异常
基本信息
- 批准号:9088503
- 负责人:
- 金额:$ 15.5万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2012
- 资助国家:美国
- 起止时间:2012-07-01 至 2017-06-30
- 项目状态:已结题
- 来源:
- 关键词:Acute leukemiaAdaptor Signaling ProteinAddressAdvisory CommitteesAffectAllelesBackBasic ScienceBindingBiological AssayBlast PhaseBone Marrow CellsCD34 geneCancer BiologyCell LineCell LineageCell membraneCellsClinicalCo-ImmunoprecipitationsColony-forming unitsConfocal MicroscopyCore FacilityCytokine ActivationDevelopmentDiseaseDoctor of PhilosophyDominant-Negative MutationEnvironmentErythrocytosesExhibitsExonsFamilyFeedbackFlow CytometryFrequenciesGeneticGoalsGrowthHematologic NeoplasmsHematologyHematopoiesisHematopoietic stem cellsHemorrhagic ThrombocythemiaHeterozygoteInvestigationJAK2 geneLaboratoriesLeadLeukocytosisLinkMPL geneMentorsMorbidity - disease rateMusMutationMyelogenousMyeloproliferative diseaseNormalcyPH DomainPathogenesisPathway interactionsPatientsPhenotypePhysiciansPlayPolycythemia VeraPrimary MyelofibrosisPrincipal InvestigatorProlinePropertyProteinsRegulationRegulatory ElementResearchResearch PersonnelResourcesRoleSamplingScientistSignal TransductionSomatic MutationSplenomegalyStructureTerminator CodonThrombopoietinTrainingTraining ProgramsTransplantationTyrosineUniversitiesVariantWashingtonWorkcareercellular transductioncohortcollaborative environmentcytokineeffective therapyfeedingfollow-upin vivoinsightmembermouse modelmutantnovelplatelet protein P47post-doctoral trainingprogenitorprogramsretroviral transductionsrc Homology Region 2 Domain
项目摘要
DESCRIPTION (provided by applicant): This proposal outlines a 5-year training program for the successful transition of the investigator to an independent physician-scientist. The principal investigator completed Ph.D. and postdoctoral training in cancer biology and signal transduction, as well as structured clinical training in hematology, and plans to pursue an academic career investigating the pathogenesis of hematologic malignancies. The training plan proposed here will expand upon his clinical and scientific background and provide him access to a supportive environment that will prepare him for a career as an independent investigator. The research program described here focuses on the functional characterization of LNK mutations in myeloproliferative neoplasms (MPNs). The applicant will be mentored by Dr. Dan Link, a recognized leader in the investigation of normal and leukemic hematopoiesis. An advisory committee consisting of basic science and clinical/translational experts in hematology will provide additional scientific and career advice. Dysregulated JAK-STAT signaling is a hallmark of MPNs. Recent work has led to the identification of novel mutations in LNK, a negative regulator of JAK-STAT signaling, in MPNs. Therefore, the aims of this proposal are to determine the mechanisms by with LNK mutations modulate JAK-STAT signaling, and to characterize the ability of LNK mutations to contribute to MPN pathogenesis. To accomplish these goals, the investigator will evaluate JAK-STAT signaling in cell lines, murine bone marrow cells, and primary cells from MPN patients bearing LNK mutations. In addition, murine models will be developed, in order to determine how LNK mutations contribute to the development of myeloproliferatve disease in vivo. These studies will provide new mechanistic insights in the pathogenesis of MPNs, and potentially lead to the development of more effective treatment options for patients with MPNs. The applicant's laboratory is well equipped for these studies, and Washington University provides a rich environment for the training and development of the investigator. Access to core facilities and other scientific resources, as well as availability of clinical samples, is exceptional. Thus, the proposed studies and training environment will facilitate the candidate's long-term goal to become a successful independent investigator.
描述(由申请人提供):该提案概述了一个为期 5 年的培训计划,旨在使研究者成功过渡为独立的医师科学家。主要研究者完成了博士学位。癌症生物学和信号转导方面的博士后培训,以及血液学方面的结构化临床培训,并计划从事研究血液恶性肿瘤发病机制的学术生涯。这里提出的培训计划将扩展他的临床和科学背景,并为他提供支持性环境,为他作为独立研究者的职业生涯做好准备。 这里描述的研究项目重点关注骨髓增生性肿瘤 (MPN) 中 LNK 突变的功能特征。申请人将得到 Dan Link 博士的指导,他是正常和白血病造血研究领域公认的领导者。由血液学基础科学和临床/转化专家组成的咨询委员会将提供额外的科学和职业建议。 JAK-STAT 信号传导失调是 MPN 的一个标志。最近的工作发现了 MPN 中 LNK 的新突变,LNK 是 JAK-STAT 信号传导的负调节因子。因此,本提案的目的是确定 LNK 突变调节 JAK-STAT 信号传导的机制,并表征 LNK 突变促进 MPN 发病机制的能力。为了实现这些目标,研究人员将评估携带 LNK 突变的 MPN 患者的细胞系、小鼠骨髓细胞和原代细胞中的 JAK-STAT 信号传导。此外,还将开发小鼠模型,以确定 LNK 突变如何促进体内骨髓增生性疾病的发展。这些研究将为 MPN 的发病机制提供新的机制见解,并有可能为 MPN 患者开发更有效的治疗方案。 申请人的实验室为这些研究配备了良好的设备,华盛顿大学为研究者的培训和发展提供了丰富的环境。使用核心设施和其他科学资源以及临床样本的可用性非常出色。因此,拟议的学习和培训环境将促进候选人成为一名成功的独立研究者的长期目标。
项目成果
期刊论文数量(2)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Stephen Tracy Oh其他文献
Stephen Tracy Oh的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Stephen Tracy Oh', 18)}}的其他基金
DYSREGULATED NFKB PATHWAY SIGNALING IN MYELOPROLIFERATIVE NEOPLASMS
骨髓增生性肿瘤中 NFKB 通路信号传导失调
- 批准号:
9448313 - 财政年份:2017
- 资助金额:
$ 15.5万 - 项目类别:
DYSREGULATED NFKB PATHWAY SIGNALING IN MYELOPROLIFERATIVE NEOPLASMS
骨髓增生性肿瘤中 NFKB 通路信号传导失调
- 批准号:
10321938 - 财政年份:2017
- 资助金额:
$ 15.5万 - 项目类别:
ACQUISITION OF A SINGLE CELL MASS CYTOMETER (CYTOF)
购买单细胞质谱仪 (CYTOF)
- 批准号:
8640344 - 财政年份:2014
- 资助金额:
$ 15.5万 - 项目类别:
ABERRANT JAK-STAT SIGNALING DUE TO LNK MUTATIONS IN MYELOPROLIFERATIVE NEOPLASMS
骨髓增生性肿瘤中 LNK 突变导致 JAK-STAT 信号异常
- 批准号:
8686926 - 财政年份:2012
- 资助金额:
$ 15.5万 - 项目类别:
ABERRANT JAK-STAT SIGNALING DUE TO LNK MUTATIONS IN MYELOPROLIFERATIVE NEOPLASMS
骨髓增生性肿瘤中 LNK 突变导致 JAK-STAT 信号异常
- 批准号:
8299207 - 财政年份:2012
- 资助金额:
$ 15.5万 - 项目类别:
ABERRANT JAK-STAT SIGNALING DUE TO LNK MUTATIONS IN MYELOPROLIFERATIVE NEOPLASMS
骨髓增生性肿瘤中 LNK 突变导致 JAK-STAT 信号异常
- 批准号:
8448195 - 财政年份:2012
- 资助金额:
$ 15.5万 - 项目类别:
ABERRANT JAK-STAT SIGNALING DUE TO LNK MUTATIONS IN MYELOPROLIFERATIVE NEOPLASMS
骨髓增生性肿瘤中 LNK 突变导致 JAK-STAT 信号异常
- 批准号:
8882524 - 财政年份:2012
- 资助金额:
$ 15.5万 - 项目类别:
PRE-AND POSTGRADUATE TRAINING IN MOLECULAR HEMATOLOGY
分子血液学学前和研究生培训
- 批准号:
9918435 - 财政年份:1975
- 资助金额:
$ 15.5万 - 项目类别:
Pre-and Postgraduate Training in Molecular Hematology
分子血液学预科和研究生培训
- 批准号:
10413815 - 财政年份:1975
- 资助金额:
$ 15.5万 - 项目类别:
Pre-and Postgraduate Training in Molecular Hematology
分子血液学预科和研究生培训
- 批准号:
10676759 - 财政年份:1975
- 资助金额:
$ 15.5万 - 项目类别:
相似国自然基金
ARRB调控Wnt/β-catenin信号通路诱导血管内皮细胞necroptosis在非小细胞肺癌外渗与转移中的作用及机制研究
- 批准号:81902350
- 批准年份:2019
- 资助金额:21.0 万元
- 项目类别:青年科学基金项目
SH3结构域蛋白Dlish调控果蝇Hippo信号通路的分子机制研究
- 批准号:31801190
- 批准年份:2018
- 资助金额:23.0 万元
- 项目类别:青年科学基金项目
锚定蛋白ENH调控eNOS磷酸化在血管重构中的作用及机制研究
- 批准号:31871399
- 批准年份:2018
- 资助金额:59.0 万元
- 项目类别:面上项目
内化接头蛋白HIP1R介导神经元树突生长和分支的作用及其机制研究
- 批准号:31871418
- 批准年份:2018
- 资助金额:60.0 万元
- 项目类别:面上项目
接头蛋白GAB1通过SAPKs信号通路调节血管平滑肌细胞自噬参与动脉粥样硬化的机制研究
- 批准号:81700421
- 批准年份:2017
- 资助金额:20.0 万元
- 项目类别:青年科学基金项目
相似海外基金
NOT-gated CAR T cells to overcome on-target, off-tumor toxicity in AML
非门控 CAR T 细胞可克服 AML 中的靶向、肿瘤外毒性
- 批准号:
10524625 - 财政年份:2022
- 资助金额:
$ 15.5万 - 项目类别:
Targeting an RNA Binding Protein Network in Acute Myeloid Leukemia
靶向急性髓系白血病中的 RNA 结合蛋白网络
- 批准号:
10171812 - 财政年份:2020
- 资助金额:
$ 15.5万 - 项目类别:
Targeting an RNA Binding Protein Network in Acute Myeloid Leukemia
靶向急性髓系白血病中的 RNA 结合蛋白网络
- 批准号:
10626928 - 财政年份:2020
- 资助金额:
$ 15.5万 - 项目类别:
Targeting an RNA Binding Protein Network in Acute Myeloid Leukemia
靶向急性髓系白血病中的 RNA 结合蛋白网络
- 批准号:
10408047 - 财政年份:2020
- 资助金额:
$ 15.5万 - 项目类别:
Exploiting NKG2C on adaptive NK cells for Immunotherapy
利用适应性 NK 细胞上的 NKG2C 进行免疫治疗
- 批准号:
9920000 - 财政年份:2019
- 资助金额:
$ 15.5万 - 项目类别: